Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity.
Rahul V ParghaneChinna NaikSanjay TaloleAnuja DesmukhDevendra ChaukarSharmila BanerjeeSandip BasuPublished in: Head & neck (2019)
The results demonstrated that, 177 Lu-DOTATATE is a potentially efficacious and safe therapeutic option in SSTR avid metastatic MTC patients.